Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome

Metabolism: Clinical and Experimental

Volumn 46, Issue 4, 1997, Pages 454-457

  Velazquez, Elsy M ^b   Mendoza, Soaira G ^b   Wang, Ping ^b   Glueck, Charles J ^a  

^a JEWISH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GLAFORNIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LUTEINIZING HORMONE; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FIBRINOLYSIS; HIGH RISK PATIENT; HIRSUTISM; HUMAN; HYPERINSULINEMIA; OBESITY; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

EID: 0030893613     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90066-4     Document Type: Article

References (34)

1. Sprengers DE, Kluft C: Plasminogen activators and inhibitors. Blood 69:381-387, 1987
2. Hamsten A, Winman B, deFaire U, et al: Increased plasma levels of a rapid inhibitor of tissue activator in young survivors of myocardial infarction. N Engl J Med 313:1557-1563, 1985
3. Aznar J, Estelles A, Tormo G, et al: Plasminogen activator inhibitor and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59:535-541, 1988
4. Glueck CJ, Rorick MH, Schmerler M, et al: Hypofibrinolytic and atherogenic risk factors for stroke. J Lab Clin Med 125:319-325, 1995
5. Hamsten A, deFaire U, Walldius G, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987
6. Vague P, Juhan-Vague Y, Ailland MF, et al: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor levels, plasma insulin, and relative body weight in normal and obese subjects. Metabolism 35:250-253, 1986
7. Juhan-Vague Y, Alessi MC, Vague P: Increased plasminogen activator 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462, 1991
8. McGill JB, Schneider DJ, Arfken CL, et al: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43:104-109, 1994
9. Landin K, Tengborn L, Chmielewska J, et al: The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 65:130-133, 1991
10. Potter van Loon BJ, Kluft C, Radder JK, et al: The cardiovascular risk factor plasminogen activator inhibitor 1 is related to insulin resistance. Metabolism 42:945-949, 1993
11. Negri M, Sheiban Y, Arigliano PL, et al: Interrelation between angiographie severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor 1. Am J Cardiol 72:397-401, 1993
12. Flack JM, Sowers JR: Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med 91:115-215, (suppl 1A) 1991
13. Zavaroni Y, Bonora E, Pagliara M, et al: Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320:702-706, 1989
14. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome p450c17alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617-623, 1996
15. Vague P, Juhan-Vague Y, Alessi MC, et al: Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic subjects. Thromb Haemost 57:326-328, 1987
16. Grant PJ, Stickland MH, Booth NA, et al: Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor 1 in type 2 diabetic patients. Diabetic Med 8:361-365, 1991
17. Landin K, Tengborn L, Smith U: Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic euglycemic clamp in man. Thromb Haemost 71:783-787, 1994
18. Dahlgren E, Janson PO, Johansson S, et al: Hemostatic and metabolic variables with polycystic ovary syndrome. Fertil Steril 61:455-460, 1994
19. Velazquez EM, Mendoza S, Hamer T, et al: Metformin therapy in women with polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating menstrual regularity and pregnancy. Metabolism 43:647-655, 1994
20. Utiger RD: Insulin and the polycystic ovary syndrome. N Engl J Med 335:657-820, 1996
21. Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Endocrinol Metab 21:440-447, 1961
22. Glueck CJ, Glueck HI, Tracy T, et al: Relationship between Lp(a), lipids, apolipoproteins, and fibrinolytic activity in 191 hyperlipidemic patients. Metabolism 42:236-246, 1993
23. Glueck CJ, Glueck HI, Mieczkowski L, et al: Familial high plasminogen activator inhibitor with hypofibrinolysis: A new pathophysiologic cause of osteonecrosis. Thromb Haemost 69:460-465, 1993
24. Snedecor GW, Cochran WG: Statistical Methods (ed 7). Ames, IA, Iowa State University Press, 1980
25. Mendoza S, Velazquez E, Osona A, et al: Post-menopausal cyclic estrogen-progestin therapy lowers lipoprotein (a). J Lab Clin Med 123:837-841, 1994
26. Anfosso F, Alessi MC, Nalbone G, et al: Up regulated expression of plasminogen activator inhibitor-1 in Hep G2 cells; interrelationship between insulin and insulin-like growth factor 1. Thromb Haemost 73:268-274, 1995
27. Anfosso F, Chomiki N, Alessi MC, et al: Plasminogen activator inhibitor 1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest 91:2185-2193, 1993
28. Schneider DJ, Nordt TK, Sobel BE: Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells. Diabetes 41:890-895, 1992
29. Eliasson M, Asplund K, Evrin PE, et al: Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: The Northern Sweden MONICA Study. Metabolism 43:1579-1586, 1994
30. Anderson P, Beljefiot I, Abdelnoor M, et al: Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 44:611-616, 1995
31. Juhan-Vague I, Thompson SG, Jesperson J: Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 13:1865-1873, 1993
32. Gough SC, Rice PJ, McCormack L, et al: The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabetic Med 10:636-642, 1993
33. Glueck CJ, Glueck HI, Freiberg R, et al: High plasminogen activator inhibitor activity and hypofibrinolysis, a major cause of idiopathic osteonecrosis. Am J Hematol 45:156-166, 1994
34. Wild RA, Grubb B, Hartz A, et al: Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 54:255-259, 1990